<DOC>
	<DOCNO>NCT01071174</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled Phase I/II study ass safety silicone elastomer vaginal ring contain 25mg dapivirine .</brief_summary>
	<brief_title>A Safety Study Dapivirine Vaginal Ring Africa</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women 18 40 year age inclusive provide inform consent Available visit consent follow procedure schedule study Healthy selfreported sexually active HIVnegative On stable form contraception willing continue OR undergone surgical sterilization least 3 month prior enrollment In absence use exogenous hormone ( ) , selfreported regular menstrual cycle define minimum 21 day maximum 35 day menses Upon pelvic/speculum examination colposcopy time enrolment , cervix vagina appear normal determined investigator Asymptomatic genital infection time enrolment Willing refrain use vaginal product object within 14 day enrollment duration study Willing answer acceptability , adherence behavioural assessment throughout study Willing refrain participation research study duration participation Willing provide adequate locator information study retention purpose reachable per local standard procedure Currently pregnant last pregnancy within 3 month prior enrolment Currently breastfeed Participated research study within 60 day prior screen Previously participate HIV vaccine study Untreated urogenital infection within 2 week prior enrolment Presence abnormal physical finding vulva , vaginal wall cervix pelvic/speculum examination and/or colposcopy History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence Pap smear result screen require cryotherapy , biopsy , treatment evaluation Any Grade 2 , 3 4 baseline ( screen ) haematology , chemistry urinalysis laboratory abnormality accord DAIDS Table Grading Adverse Events Any abnormal bleeding per vagina , bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrolment Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone elastomer Any serious acute , chronic progressive disease Any condition ( ) , opinion investigator , might interfere adherence study requirement evaluation study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>HIV-1</keyword>
</DOC>